|
1
|
Power DG, Kelsen DP and Shah MA: Advanced
gastric cancer-slow but steady progress. Cancer Treat Rev.
36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim HJ, Eun JY, Jeon YW, Yun J, Kim KH,
Kim SH, Kim HJ, Lee SC, Bae SB, Kim CK, et al: Efficacy and safety
of oxaliplatin, 5-Fluorouracil, and folinic Acid combination
chemotherapy as first-line treatment in metastatic or recurrent
gastric cancer. Cancer Res Treat. 43:154–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah MA, Janjigian YY, Stoller R, Shibata
S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B,
et al: Randomized multicenter phase II study of modified docetaxel,
cisplatin, and fluorouracil (DCF) versus DCF plus growth factor
support in patients with metastatic gastric adenocarcinoma: A study
of the US gastric cancer consortium. J Clin Oncol. 33:3874–3879.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sui M, Jiao A, Zhai H, Wang Y, Wang Y, Sun
D and Li P: Upregulation of miR-125b is associated with poor
prognosis and trastuzumab resistance in HER2-positive gastric
cancer. Exp Ther Med. 14:657–663. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanner M, Hollmén M, Junttila TT, Kapanen
AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al:
Amplification of HER-2 in gastric carcinoma: Association with
Topoisomerase II alpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taniguchi N and Korekane H: Branched
N-glycans and their implications for cell adhesion, signaling and
clinical applications for cancer biomarkers and in therapeutics.
BMB Rep. 44:772–781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dall'Olio F, Malagolini N, Trinchera M and
Chiricolo M: Mechanisms of cancer-associated glycosylation changes.
Front Biosci. 17:670–699. 2012. View
Article : Google Scholar
|
|
12
|
Schultz MJ, Swindall AF and Bellis SL:
Regulation of the metastatic cell phenotype by sialylated glycans.
Cancer Metastasis Rev. 31:501–518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y and Chen X: Sialic acid metabolism
and sialyltransferases: Natural functions and applications. Appl
Microbiol Biotechnol. 94:887–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaikh FM, Seales EC, Clem WC, Hennessy
KM, Zhuo Y and Bellis SL: Tumor cell migration and invasion are
regulated by expression of variant integrin glycoforms. Exp Cell
Res. 314:2941–2950. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu J and Gu J: Significance of
β-galactoside α2,6 sialyltranferase 1 in Cancers. Molecules.
20:7509–7527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Büll C, Stoel MA, den Brok MH and Adema
GJ: Sialic acids sweeten a tumor's life. Cancer Res. 74:3199–3204.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swindall AF, Londoño-Joshi AI, Schultz MJ,
Fineberg N, Buchsbaum DJ and Bellis SL: ST6Gal-I protein expression
is upregulated in human epithelial tumors and correlates with stem
cell markers in normal tissues and colon cancer cell lines. Cancer
Res. 73:2368–2378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dall'Olio F, Chiricolo M, D'Errico A,
Gruppioni E, Altimari A, Fiorentino M and Grigioni WF: Expression
of β-galactoside α2,6 sialyltransferase and of α2,6-sialylated
glycoconjugates in normal human liver, hepatocarcinoma, and
cirrhosis. Glycobiology. 14:39–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin S, Kemmner W, Grigull S and Schlag PM:
Cell surface α2,6 sialylation affects adhesion of breast carcinoma
cells. Exp Cell Res. 276:101–110. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swindall AF and Bellis SL: Sialylation of
the Fas death receptor by ST6Gal-I provides protection against
Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem.
286:22982–22990. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuo Y, Chammas R and Bellis SL:
Sialylation of beta1 integrins blocks cell adhesion to galectin-3
and protects cells against galectin-3-induced apoptosis. J Biol
Chem. 283:22177–22185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Swindall AF, Kesterson RA, Schoeb
TR, Bullard DC and Bellis SL: ST6Gal-I regulates macrophage
apoptosis via α2-6 sialylation of the TNFR1 death receptor. J Biol
Chem. 286:39654–39662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JJ, Yi JY, Jin YB, Lee YJ, Lee JS,
Lee YS, Ko YG and Lee M: Sialylation of epidermal growth factor
receptor regulates receptor activity and chemosensitivity to
gefitinib in colon cancer cells. Biochem Pharmacol. 83:849–857.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Britain CM, Dorsett KA and Bellis SL: The
glycosyltransferase ST6Gal-I protects tumor cells against serum
growth factor withdrawal by enhancing survival signaling and
proliferative potential. J Biol Chem. 292:4663–4673. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baek DW, Kang BW, Hwang S, Kim JG, Seo AN,
Bae HI, Kwon OK, Lee SS, Chung HY and Yu W: Clinical significance
of p53 protein expression, beta-catenin expression and HER2
expression for Epstein-Barr virus-associated gastric cancer.
Chonnam Med J. 53:140–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmed S, Sami A and Xiang J: HER2-directed
therapy: Current treatment options for HER2-positive breast cancer.
Breast Cancer. 22:101–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oh DY, Jung K, Song JY, Kim S, Shin S,
Kwon YJ, Oh E, Park WY, Song SY and Choi YL: Precision medicine
approaches to lung adenocarcinoma with concomitant MET and HER2
amplification. BMC Cancer. 17:5352017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Walsh JG, Cullen SP, Sheridan C, Lüthi AU,
Gerner C and Martin SJ: Executioner caspase-3 and caspase-7 are
functionally distinct proteases. Proc Natl Acad Sci USA.
105:12815–12819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Joslin EJ, Opresko LK, Wells A, Wiley HS
and Lauffenburger DA: EGF-receptor-mediated mammary epithelial cell
migration is driven by sustained ERK signaling from autocrine
stimulation. J Cell Sci. 120:3688–3699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yk W, Cf G, T Y, Z C, Xw Z, Xx L, Nl M and
Wz Z: Assessment of ERBB2 and EGFR gene amplification
and protein expression in gastric carcinoma by immunohistochemistry
and fluorescence in situ hybridization. Mol Cytogenet. 4:142011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Apicella M, Corso S and Giordano S:
Targeted therapies for gastric cancer: Failures and hopes from
clinical trials. Oncotarget. 8:57654–57669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nemeth BT, Varga ZV, Wu WJ and Pacher P:
Trastuzumab cardiotoxicity: From clinical trials to experimental
studies. Br J Pharmacol. 174:3727–3748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan Y, Wu L, Shen S, Wu S and Burdick MM:
Effect of α2,6 sialylation on integrin-mediated adhesion of breast
cancer cells to fibronectin and collagen IV. Life Sci. 149:138–145.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hedlund M, Ng E, Varki A and Varki NM:
α2-6-Linked sialic acids on N-glycans modulate carcinoma
differentiation in vivo. Cancer Res. 68:388–394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hou S, Hang Q, Isaji T, Lu J, Fukuda T and
Gu J: Importance of membrane-proximal N-glycosylation on
integrin β1 in its activation and complex formation. FASEB J.
30:4120–4131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma M, Ma Y, Zhang GJ, Liao R, Jiang XF,
Yan XX, Bie FJ, Li XB and Lv YH: Eugenol alleviated breast
precancerous lesions through HER2/PI3K-AKT pathway-induced cell
apoptosis and S-phase arrest. Oncotarget. 8:56296–56310.
2017.PubMed/NCBI
|
|
37
|
Jandial DD, Krill LS, Chen L, Wu C, Ke Y,
Xie J, Hoang BH and Zi X: Induction of G2M arrest by Flavokawain A,
a kava chalcone, increases the responsiveness of
HER2-overexpressing breast cancer cells to herceptin. Molecules.
22:pii E462. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bahrami A, Hasanzadeh M, Hassanian SM,
ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The
potential value of the PI3K/Akt/mTOR signaling pathway for
assessing prognosis in cervical cancer and as a target for therapy.
J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Teplinsky E and Muggia F: Targeting HER2
in ovarian and uterine cancers: Challenges and future directions.
Gynecol Oncol. 135:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ikink GJ, Boer M, Bakker ER and Hilkens J:
IRS4 induces mammary tumorigenesis and confers resistance to
HER2-targeted therapy through constitutive PI3K/AKT-pathway
hyperactivation. Nat Commun. 7:135672016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT,
Chen YJ, Hsu TL, Yang PC and Wong CH: Effect of sialylation on EGFR
phosphorylation and resistance to tyrosine kinase inhibition. Proc
Natl Acad Sci USA. 112:6955–6960. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Köninki K, Barok M, Tanner M, Staff S,
Pitkänen J, Hemmilä P, Ilvesaro J and Isola J: Multiple molecular
mechanisms underlying trastuzumab and lapatinib resistance in
JIMT-1 breast cancer cells. Cancer Lett. 294:211–219. 2010.
View Article : Google Scholar : PubMed/NCBI
|
